Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lantern Pharma Inc (LTRN)

Lantern Pharma Inc (LTRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,526
  • Shares Outstanding, K 11,184
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,780 K
  • EBIT $ -20 M
  • EBITDA $ -20 M
  • 60-Month Beta 1.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.41

Options Overview Details

View History
  • Implied Volatility 388.19% (+194.94%)
  • Historical Volatility 187.61%
  • IV Percentile 71%
  • IV Rank 39.79%
  • IV High 857.88% on 02/18/26
  • IV Low 77.80% on 01/30/26
  • Expected Move (DTE 18) 0.5440 (44.05%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 151
  • Volume Avg (30-Day) 33
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 368
  • Open Int (30-Day) 304
  • Expected Range 0.6910 to 1.7790

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +185,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1100 +11.26%
on 03/27/26
2.8500 -56.67%
on 03/04/26
-1.5850 (-56.21%)
since 02/27/26
3-Month
1.1100 +11.26%
on 03/27/26
3.6000 -65.69%
on 01/09/26
-2.2450 (-64.51%)
since 12/26/25
52-Week
1.1100 +11.26%
on 03/27/26
5.7441 -78.50%
on 08/06/25
-2.3150 (-65.21%)
since 03/28/25

Most Recent Stories

More News
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Year of Clinical Validation and Strategic Expansion Across Pipeline, AI Platform Advances Towards Commercialization, and Global Trial Milestones ...

LTRN : 1.2350 (+10.27%)
New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)

The show also broadcasts across MENA and Latin America as sponsored programming.

TRN : 31.36 (+0.55%)
PETV : 0.7000 (-4.79%)
SNYR : 1.2100 (+0.01%)
ACXP : 3.50 (-6.91%)
IGC : 0.2555 (+0.08%)
VTIX : 6.83 (+2.25%)
LTRN : 1.2350 (+10.27%)
NRXP : 2.09 (-4.57%)
YYGH : 1.0700 (+3.88%)
DVLT : 0.5550 (-2.51%)
VVOS : 1.0900 (-5.22%)
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern” or the “Company”), an AI‑driven, clinical‑stage oncology company leveraging its proprietary RADR ® platform to transform the cost...

LTRN : 1.2350 (+10.27%)
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

The Planned Multicenter Phase 1 Trial Will Evaluate STAR-001 as Monotherapy and in Combination with Spironolactone in Children with Relapsed or Refractory CNS Malignancies, Including ATRT, DIPG, GBM, Medulloblastoma,...

LTRN : 1.2350 (+10.27%)
RedChip AI Investor Conference Replays Now Available Highlighting Companies Driving Innovation Across the AI Ecosystem

ORLANDO, FL / ACCESS Newswire / March 27, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays...

CMHSF : 0.4004 (-26.48%)
ZEO : 0.5820 (-2.45%)
LTRN : 1.2350 (+10.27%)
CSAI : 0.6500 (-1.96%)
SHAZ : 21.73 (-5.44%)
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET

Webcast to be held Monday, March 30th, 4:30 p.m. ET, register for the webcast here , or at the link provided below. 

LTRN : 1.2350 (+10.27%)
New to The Street Announces Broadcast of Show #739 on Bloomberg Television Across the U.S. at 6:30 PM EST

Featured Companies Include FreeCast (NASDAQ:CAST), KLED.ai, Lantern Pharma (NASDAQ:LTRN), and BlackBarn Restaurant

CAST : 3.90 (-2.01%)
RDZN : 1.0700 (unch)
SDST : 2.17 (-8.82%)
LTRN : 1.2350 (+10.27%)
VRTX : 443.16 (+2.33%)
NRXP : 2.09 (-4.57%)
DVLT : 0.5550 (-2.51%)
SGTM : 0.2382 (+9.37%)
CISO : 0.3221 (-2.10%)
RedChip Highlights Public Companies Advancing the Next Phase of AI Adoption at Virtual Investor Conference on March 19

ORLANDO, FL / ACCESS Newswire / March 16, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming AI Investor...

LTRN : 1.2350 (+10.27%)
SHAZ : 21.73 (-5.44%)
Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, today announced that CEO and President...

LTRN : 1.2350 (+10.27%)
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

Third FDA orphan designation for LP-284; Sixth overall for Lantern’s A.I.-driven precision oncology pipeline Orphan designation expands LP-284's potential for an estimated ~96,000 global...

LTRN : 1.2350 (+10.27%)

Business Summary

Lantern Pharma Inc.is a biotechnology company. It develops medicines for multi-drug treatment resistance cancers focusing on prostate and ovarian cancers. The company's drug candidate consist LP-100, LP-300 and LP-184 which are in clinical stage. Lantern Pharma Inc.is based in Dallas, Texas.

See More

Key Turning Points

3rd Resistance Point 1.6717
2nd Resistance Point 1.5583
1st Resistance Point 1.3967
Last Price 1.2350
1st Support Level 1.1217
2nd Support Level 1.0083
3rd Support Level 0.8467

See More

52-Week High 5.7441
Fibonacci 61.8% 3.9739
Fibonacci 50% 3.4271
Fibonacci 38.2% 2.8802
Last Price 1.2350
52-Week Low 1.1100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.